Skip to content

ARROWHEAD PHARMACEUTICALS, INC.: 10-Q filed 2017-02-06

What ARROWHEAD PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-02-06 (fiscal Q1 2017): 34 published measures, 68 facts as tagged in accession 0001564590-17-001023.

This filing

Form
10-Q (quarterly report)
Filed
2017-02-06
Fiscal period
fiscal Q1 2017
Accession
0001564590-17-001023 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARROWHEAD PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-31144,258,106USD
At 2016-09-30128,176,505USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-3197,763,609USD
At 2016-09-3095,579,447USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-31102,105,569USD
At 2016-09-3085,366,448USD
At 2015-12-3162,165,088USD
At 2015-09-3081,214,354USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-10-01 to 2016-12-315,296,653USD92
2015-10-01 to 2015-12-31406,612USD92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-10-01 to 2016-12-314,365,496USD92
2015-10-01 to 2015-12-3143,750USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-31-410,521,151USD
At 2016-09-30-398,435,043USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-12-3116,165,659USD
At 2016-09-3015,386,761USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-10-01 to 2016-12-312,424,442USD92
2015-10-01 to 2015-12-312,380,343USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-14,901,887USD92
2015-10-01 to 2015-12-31-19,341,270USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-31106,230,353USD
At 2016-09-3090,502,543USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-3136,998,092USD
At 2016-09-3025,643,794USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-12-313,698,297USD
At 2016-09-3012,232,906USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-12-3121,739,761USD
At 2016-09-3022,164,868USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-12-3160,000USD
At 2016-09-3075,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-10-01 to 2016-12-3119,267,383USD92
2015-10-01 to 2015-12-3119,385,020USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-12-3174,413,040shares
At 2016-09-3069,746,685shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-12-31508,303,137USD
At 2016-09-30493,844,909USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-12-31-185,159USD
At 2016-09-307,449USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2016-12-3197,208,421USD
At 2016-09-3095,024,259USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2016-12-3121,438,922USD
At 2016-09-3019,899,521USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-12-315,273,263USD
At 2016-09-304,512,760USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-12-31122,333USD
At 2016-09-30122,333USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-12-31200,000USD
At 2016-09-30200,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2016-12-314,762,105USD
At 2016-09-304,587,467USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-12,086,108USD92
2015-10-01 to 2015-12-31-19,264,414USD92

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-12,086,108USD92
2015-10-01 to 2015-12-31-19,264,414USD92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-12,278,716USD92
2015-10-01 to 2015-12-31-19,218,596USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-311,854,174USD92
2015-10-01 to 2015-12-311,951,609USD92

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-10-01 to 2016-12-31425,107USD92
2015-10-01 to 2015-12-31438,991USD92

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2016-10-01 to 2016-12-311,306,800USD92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-10-01 to 2016-12-312,815,779USD92
2015-10-01 to 2015-12-3176,856USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-10-01 to 2016-12-3112,500,000USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-15,000USD92
2015-10-01 to 2015-12-311,054,719USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-4,648,013USD92
2015-10-01 to 2015-12-31257,216USD92

Inspect the source

Entity
ARROWHEAD PHARMACEUTICALS, INC. / CIK 0000879407
Captured
2026-09-20T05:01:27.924Z
SEC response SHA-256
df8855dae0055b71bd49c85d7ebc47f72ea6d71536d6bfd857bed2fe95364863

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000879407.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))